- Male or female
- Diagnosis of pediatric glaucoma or elevated intraocular pressure.
- Evidence of a personally signed and dated informed consent document indicating that
the subject (and/or a legally acceptable representative) has been informed of all
pertinent aspects of the study. A signed and dated assent will be required where
applicable according to local laws.
For treated subjects only:
- Continuously treated with latanoprost for at least 1 month within the year prior to
the baseline examination.
For untreated subjects only:
- Continuously treated with latanoprost or other topical prostaglandin analogues for
less than one month prior to the baseline examination (based on the best knowledge of
treating ophthalmologists), and unlikely to be treated with latanoprost or other
topical prostaglandin analogues during the three-year study period; OR
- No prior treatment with latanoprost or other topical prostaglandin analogues, and
unlikely to be treated with latanoprost or other topical prostaglandin analogues
during the three-year study period.
- Unable/unwilling to comply with protocol.
- Pregnant or nursing females at baseline.
- For treated subjects only: a history of allergy or hypersensitivity to any of the
ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium
chloride).